Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus

Lupus

Volumn 11, Issue 4, 2002, Pages 221-226

  Fureder W ^a   Firbas, U ^b   Nichol, J L ^c   Pistillo, J ^c   Winkler, S ^a   Hiesberger, H ^b   Sperr, W R ^a   Smolen, J ^b   Schett, G ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c AMGEN INC   (United States)

Author keywords

Autoantibodies; Thrombocytopenia; Thrombopoietin

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C4; THROMBOPOIETIN; THROMBOPOIETIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLATELET COUNT; THROMBOPOIETIN;

EID: 0036255815     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu177oa     Document Type: Article

References (29)

1. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl
2. Thrombopoietin: The primary regulator of platelet production
3. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy induced thrombocytopenia
4. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in platelet mass during busulfan-induced thrombocytopenia in the rabbit
5. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura
6. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis
7. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insights into the regulation of platelet production
8. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction
9. Serum thombopoietin levels in patients with aplastic anaemia
10. The hematologic aspects of disseminated (systemic) lupus erythematosus
11. Hematologic and lymphoid abnormalities in systemic lupus erythematosus
12. Hematologic aspects of systemic lupus erythematosus. Current concepts
13. Cell-mediated amegakaryocytic thrombocytopenia associated with systemic lupus erythematosus
14. Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of SLE
15. Pure red cell aplasia in a patient with systemic lupus erythematosus
16. Suppression of haematopoiesis by IgG autoantibodies from patients with systemic lupus erythematosus
17. An antibody that inhibits in vitro bone marrow proliferation in a patient with systemic lupus erythematosus and aplastic anaemia
18. Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus
19. The 1982 revised criteria for the classification of systemic lupus erythematosus
20. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score
21. Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the mpl ligand
22. Mortality risk with specific clinical manifestations of systemic lupus erythematosus
23. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality
24. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura
25. Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant
26. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease
27. Elevated thrombopoietin serum levels in patients with inflammatory bowel disease
28. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia
29. The effect of steroid and intravenous immunoglobulin on thrombopoietin levels in pediatric patients with immune thrombocytopenic purpura